TY - JOUR
T1 - MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice
AU - Fernandes, Marie
AU - Hoggard, Brynna
AU - Jamme, Philippe
AU - Paget, Sonia
AU - Truong, Marie José
AU - Grégoire, Valérie
AU - Vinchent, Audrey
AU - Descarpentries, Clotilde
AU - Morabito, Angela
AU - Stanislovas, Justas
AU - Farage, Enoir
AU - Meneboo, Jean Pascal
AU - Sebda, Shéhérazade
AU - Bouchekioua-Bouzaghou, Katia
AU - Nollet, Marie
AU - Humez, Sarah
AU - Perera, Timothy
AU - Fromme, Paul
AU - Grumolato, Luca
AU - Figeac, Martin
AU - Copin, Marie Christine
AU - Tulasne, David
AU - Cortot, Alexis B.
AU - Kermorgant, Stéphanie
AU - Kherrouche, Zoulika
N1 - Publisher Copyright:
© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
PY - 2023/11
Y1 - 2023/11
N2 - Exon skipping mutations of the MET receptor tyrosine kinase (METex14), increasingly reported in cancers, occur in 3–4% of non–small-cell lung cancer (NSCLC). Only 50% of patients have a beneficial response to treatment with MET-tyrosine kinase inhibitors (TKIs), underlying the need to understand the mechanism of METex14 oncogenicity and sensitivity to TKIs. Whether METex14 is a driver mutation and whether it requires hepatocyte growth factor (HGF) for its oncogenicity in a range of in vitro functions and in vivo has not been fully elucidated from previous preclinical models. Using CRISPR/Cas9, we developed a METex14/WT isogenic model in nontransformed human lung cells and report that the METex14 single alteration was sufficient to drive MET-dependent in vitro anchorage-independent survival and motility and in vivo tumorigenesis, sensitising tumours to MET-TKIs. However, we also show that human HGF (hHGF) is required, as demonstrated in vivo using a humanised HGF knock-in strain of mice and further detected in tumour cells of METex14 NSCLC patient samples. Our results also suggest that METex14 oncogenicity is not a consequence of an escape from degradation in our cell model. Thus, we developed a valuable model for preclinical studies and present results that have potential clinical implication.
AB - Exon skipping mutations of the MET receptor tyrosine kinase (METex14), increasingly reported in cancers, occur in 3–4% of non–small-cell lung cancer (NSCLC). Only 50% of patients have a beneficial response to treatment with MET-tyrosine kinase inhibitors (TKIs), underlying the need to understand the mechanism of METex14 oncogenicity and sensitivity to TKIs. Whether METex14 is a driver mutation and whether it requires hepatocyte growth factor (HGF) for its oncogenicity in a range of in vitro functions and in vivo has not been fully elucidated from previous preclinical models. Using CRISPR/Cas9, we developed a METex14/WT isogenic model in nontransformed human lung cells and report that the METex14 single alteration was sufficient to drive MET-dependent in vitro anchorage-independent survival and motility and in vivo tumorigenesis, sensitising tumours to MET-TKIs. However, we also show that human HGF (hHGF) is required, as demonstrated in vivo using a humanised HGF knock-in strain of mice and further detected in tumour cells of METex14 NSCLC patient samples. Our results also suggest that METex14 oncogenicity is not a consequence of an escape from degradation in our cell model. Thus, we developed a valuable model for preclinical studies and present results that have potential clinical implication.
KW - hepatocyte growth factor
KW - lung cancer
KW - preclinical models
KW - targeted therapies
KW - transcriptomic
KW - tyrosine kinase receptor
UR - https://www.scopus.com/pages/publications/85164782962
U2 - 10.1002/1878-0261.13397
DO - 10.1002/1878-0261.13397
M3 - Article
C2 - 36799689
AN - SCOPUS:85164782962
SN - 1574-7891
VL - 17
SP - 2257
EP - 2274
JO - Molecular Oncology
JF - Molecular Oncology
IS - 11
ER -